The Very Large Database of Lipids (VLDL) (VLDL)
Closer examination of granular lipid data in a large population offers numerous opportunities to generate new knowledge, ranging from studies examining concordance between commonly used lipid parameters to phenotypic characterization of rare or extreme disorders of lipid metabolism, opening possibilities to better personalize future treatment of abnormal blood lipids.
The Very Large Database of Lipids (VLDL) includes adults and children who were clinically referred for a Vertical Auto Profile (VAP).
The VAP test (VAP Diagnostis Lab, Birmingham, Alabama, USA) directly measures cholesterol concentrations of low density lipoprotein, very low density lipoprotein, intermediate density lipoprotein, high density lipoprotein, their subfractions, and lipoprotein(a). Triglycerides in the database are directly measured using the Abbott ARCHITECT C‐8000 system (Abbott Park, Illinois, USA). Lipid distributions in the database closely match those from the population-representative National Health and Nutrition Examination Survey (NHANES).
This database was investigator-initiated. Only de-identified data reach the investigational site. The first data harvest was in 2011 and the second in 2016. The master database is housed at The Johns Hopkins Hospital in Baltimore, Maryland, and maintained by Drs. Jones and Martin. Only electronic data, and not biospecimens, are sent to Hopkins. The academic investigators have unrestricted access to study data, take responsibility for the accuracy of analyses, and have authority over manuscript preparation and submission.
The variables currently in the VLDL database are testing date, age, sex, fasting/nonfasting, and components of the VAP test. From these primary variables, many additional variables were derived for inclusion in the master database (e.g., non-HDL-C, Friedewald LDL-C, TC/HDL-C, etc.). Other analytes measured by validated assays in subsets of the VLDL database include apoB, apoA1, hsCRP, homocysteine, uric acid, insulin, hemoglobin A1c, 25-hydroxy vitamin D, cystatin C, Liproprotein-associated Phosphatase (Lp-PLA2), Thyroid Stimulating Hormone (TSH), free T3 and T4, pro- Brain Natiuretic Peptide (BNP), direct bilirubin, Creatine Phosphokinase (CPK), creatinine and other components of the comprehensive metabolic panel, magnesium, and phosphate.
In the current database, each record represents a unique patient. The 1st available VAP test for each patient is included. To meet the needs of a variety of research questions, we are prospectively planning to organize harvest 2 data into 3-year interval datasets (i.e., VLDL 2006-2008, 2009-2011, VLDL 2012-2014, etc), a summation dataset (first VAP test for each patient), serial lab dataset (patients who have had repeated testing), and ancillary datasets (subsets of patients with coexisting data on other measures such as apolipoproteins, vitamin D, hs-C-Reactive Protein (CRP), TSH/T4, etc).
Individual VLDL studies are based on a priori hypotheses or aims with statistical analysis plans (SAPs) peer-reviewed prior to execution. In the expandable "Detailed Description" section below, the VLDL investigators will periodically register individual studies and update their status on clinicaltrials.gov.
|Lipid Disorders and Lipid Measurement|
|Study Design:||Observational Model: Other
Time Perspective: Cross-Sectional
|Official Title:||The Very Large Database of Lipids (VLDL): A Clinical Laboratory Big Data Project|
- all-cause mortality [ Time Frame: up to 9 years from time of baseline lipid profile ]
|Actual Study Start Date:||April 2006|
|Estimated Study Completion Date:||April 2020|
|Primary Completion Date:||April 2016 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01698489
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21287|
|Study Director:||Steven R Jones, MD||Johns Hopkins University|
|Principal Investigator:||Seth S Martin, MD, MHS||Johns Hopkins University|